Send to

Choose Destination
J Neuropsychiatry Clin Neurosci. 2015;27(2):133-8. doi: 10.1176/appi.neuropsych.13070155.

A trial of d-cycloserine to treat the social deficit in older adolescents and young adults with autism spectrum disorders.

Author information

From the Dept. of Psychiatry and Behavioral Sciences, Eastern Virginia Medical School, Norfolk, Virginia (MU, LO, KH, SID); and Virginia Commonwealth University, Richmond, Virginia (PM).


Autism spectrum disorders are difficult for older adolescents and young adults as impaired social communication affects the transition to adult life. d-Cycloserine, a partial glycine agonist at the N-methyl-d-aspartic acid receptor, was tested in a double-blind randomized trial in 20 older adolescents and young adults with autism spectrum disorders using two dosing strategies (50 mg daily versus 50 mg weekly) for 8 weeks with a 2-week follow-up after discontinuation. d-Cycloserine caused statistically and clinically significant improvement with no differentiation between dosing strategies on the Social Responsiveness Scale and the Aberrant Behavior Checklist before and after d-cycloserine administration.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center